Proactive Investors - Run By Investors For Investors

Allergy Therapeutics reports positive results from early-stage study of dust mite jab

Not only was Acarovac seen to be safe and well-tolerated in the phase I trial, but the 16 patients taking part also enjoyed a “significant improvement” in their symptoms
dust mite
Allergy was spun out of SmithKline Beecham (now GSK) back in 1999

Allergy Therapeutics PLC (LON:AGY) has reported positive results from the early-stage study of Acarovac – its dust mite allergy jab.

The drug was tested in 16 patients as part of the phase I trial to assess its safety and tolerability.

Sufferers were given seven injections over a 6-12 week period.

READ: Allergy thinks its adjuvant system could be used in fight against cancer

Allergy said Acarovac was well tolerated and had a satisfactory safety profile, with reported adverse events similar to what has been observed with similar vaccines.

In addition to those primary endpoints, researchers also found that the injection had a “significant improvement” on patients’ total symptom scores.

“The success of our clinical trial in house dust mite-induced allergic rhinitis is encouraging news for the many patients who continue to suffer with the symptoms caused by house dust mite allergy, and supports our ambition to provide a global therapy for the important US, China and EU markets,” said chief executive Manuel Llobet.

“Based on the unique triple-combination of our allergoids, and the adjuvant system MPL and MCT we believe Acarovac MPL could build on our success in dust mite immunotherapy and we look forward to progressing towards phase II clinical studies.”

In a note to clients, analysts at ‘house broker’ finnCap commented: “This study will allow the company to proceed with a larger Phase II dose ranging study, which we expect to begin in late 2019/2020. We make no change to forecasts and reiterate our target price of 40p.”

In afternoon trading, shares in Allergy Therapeutics were changing hands at 12.50p each.

 -- Adds analyst comment, share price --

View full AGY profile View Profile

Allergy Therapeutics PLC Timeline

Related Articles

Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
genedrive device
May 23 2019
Here we take a closer look at Genedrive PLC (LON:GDR)
A woman with severe depression
April 25 2019
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use